Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.
Total raised: $3.2M
Investors 3
| Date | Name | Website |
| 01.12.2024 | SeedFolio | seedfolio.... |
| - | Endless Fr... | endlessfro... |
| 06.05.2026 | Anges Québ... | angesquebe... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.09.2024 | Seed | $3.2M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.09.2024 | HDAX Therapeutics (Life Sciences, '22-23) has announced their first closing of an oversubscribed $3.2M Seed Round. | - |
| 05.09.2024 | HDAX Therapeutics Holds First Closing of USD$3.2M Seed Financing | HDAX Therapeutics, a Toronto, Canada-based biotechnology company, held the first closing of a US$3.2M (CA$4.3M) Seed funding. The round was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners, with participation from Eos B... |
| - | HDAX Therapeutics | “HDAX Therapeutics novel modality unlocks a never-seen-before binding mechanism to key biological molecules.” |